TOP HEADLINES

Editor's Corner

Alnylam bets $200M on its commercial future with new plant

RNAi biotech Alnylam Pharmaceuticals is planning to spend $200 million on a manufacturing plant in a bet that its pipeline therapies will find their way to market in the coming years.

Clovis looks to rebuild the case for its cancer drug at FDA panel

Clovis Oncology, whose market value has plummeted by more than 80% over the past year, has secured a date with FDA advisers to make the case that its lung cancer treatment merits approval despite some disappointing data.

U.K.'s Shield pulls off an IPO but dramatically cuts its flotation price

In a sign of the continuing headwinds for biotech, Shield Therapeutics has had to cut both its price and its original aims to see through its U.K. IPO.

Apellis raises $47M after pulling the plug on an $86M IPO

Louisville, KY, drug developer Apellis Pharmaceuticals raised $47.1 million in venture cash to push its pipeline of treatments for rare diseases, regrouping after aborting an effort to go public earlier this month.

Novartis buys EU rights to Pfizer's Remicade biosimilar, targeting Merck

Novartis, which won the U.S.'s first-ever biosimilar approval last year, is expanding its reach in Europe, buying the continental rights to a Pfizer-developed take on the blockbuster Remicade.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

Pfizer Consumer Healthcare announced the launch of joint health and wellness innovation program that will enable 10 med tech startups to utilize the San Francisco office of tech industry incubator Galvanize.

FiercePharma

India's Sun Pharmaceutical saw its sales in the U.S., its largest market, continue to fall as problems with a key plant in India have yet to be resolved. U.S. sales were off 11% to $486 million in the quarter ended Dec. 31, 2015, India's largest drugmaker reported today.

'